Paragon 28® expands its JAWS™ Nitinol Staple offering to address corrections of the midfoot and hindfoot

ENGLEWOOD, Colo.April 9, 2018 /PRNewswire/ — Since its inception, Paragon 28® has obsessed over every aspect of foot and ankle surgery. Committed to creating tailored solutions to improve surgical outcomes, Paragon 28® has launched innovative products and instrumentation to help streamline medical procedures, allow surgeons flexibility in technique and approach, and facilitate reproducible results benefitting both the surgeon and patient.

Paragon 28® designed the JAWSTM Nitinol Staple System for use in an osteotomy, arthrodesis and fragment fixation of bones and joints of the foot including fixation of small bone fragments.

The JAWSTM Nitinol Staple System uses superelastic nitinol and a simple insertion method to gain rigid compression across an osteotomy site. Unlike many competitive implants, the JAWSTM Nitinol Staple System has a lightweight titanium inserter that allows the surgeon to fully seat the staple before it is released from the inserter.  This eliminates the need to tamp following insertion which can crush bone surrounding the legs weakening the construct.

Compression is achieved upon insertion; no heating or electrical activation is required.

A low profile bridge helps minimize soft tissue irritation while the sharp-tooth geometry increases pull out resistance and helps resist migration during healing. Paragon 28® optimized the shape, angulation, and size of the staple legs to distribute compression evenly along the length of the legs. This helps to eliminate plantar gapping and ensures consistent force across the osteotomy site.

All instrumentation for the JAWSTM Nitinol Staple System comes in a self-contained, disposable, sterile kit. The JAWS TMNitinol Staple comes pre-loaded on the inserter to help facilitate a quick and simple surgery. An auxiliary instrument set is also available which includes trial sizers, instrumentation used for decortication and the JAWSTM Compressor. The JAWS™ Compressor is available to assist the surgeon in gaining pre-compression in midfoot to hindfoot fusions.

The JAWS TM Nitinol Staple System now offers surgeons 8 mm Straight and Angled, 10 mm Straight and Angled, 15 mm Straight, 18 mm Straight, 20 mm Straight, and 25 mm Straight options to address a multitude of indications throughout the foot.

Product Page: http://www.paragon28.com/products/jaws-nitinol-staple-system/

CONTACT: Jim Edson, Vice President of Product Management and Marketing, jedson@paragon28.com

 

SOURCE Paragon 28

(PRNewsfoto/Paragon 28)

Related Links

http://www.paragon28.com/products/jaws-nitinol-staple-system

OrthoPediatrics Corp. Announces Sponsorship of 2018 EPOS Meeting and Lunch Symposium

WARSAW, Ind., April 09, 2018 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (NASDAQ:KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, today announced it will continue its Diamond sponsorship for the 37th Annual European Paediatric Orthopaedic Society (EPOS) meeting, which will take place April 11 – 14 in Oslo, Norway. OrthoPediatrics has been a leading sponsor of the Society since the Company’s inception.

At the meeting, OrthoPediatrics will also sponsor a lunch symposium titled “Management of Open Fractures in Children”, featuring a panel of key opinion leaders from around the world. The panelists will discuss the most frequent types of fractures, guidelines for antibiotic use, evidence-based surgical treatment and the management of soft tissue injuries in open fractures in children.  The panel will be moderated by Dr. Pierre Journeau, with additional discussion and case presentations by Drs. Annelie Weinberg, Manoj Ramachandran, and Manon Bachy.

OrthoPediatrics’ President & CEO Mark Throdahl, commented, “We are pleased to continue our leading support of EPOS, one of the world’s largest pediatric orthopedic scientific organizations. This society has remained steadfastly dedicated to elevating the quality of care for children with orthopedic conditions. OrthoPediatrics has shared this mission since our inception, and so we are proud to continue supporting the clinical education of pediatric surgeons as we work together to improve the lives of children with orthopedic conditions around the world.”

About OrthoPediatrics Corp. 
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 24 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, scoliosis and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 37 countries outside the United States.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com

Esaote Introduces new extremity MRI systems, O-scan Premium and O-scan Light at the AAOE 2018 Annual conference

FISHERS, Ind.April 6, 2018 /PRNewswire/ — Responding to the market need for high performance extremity MRI systems, Esaote launches the new O-scan Premium* extremity MRI system and its value version, the O-scan Light*. The O-scan Premium and the O-scan Light will be shown at the American Association of Orthopaedic Executives (AAOE), Hyatt Regency, Orlando, Booth #219.

Esaote is a world leader in dedicated MRI with over 30 years of innovation in the field of musculoskeletal MRI, producing cost-effective systems that provide clinicians with outstanding image quality, flexibility, ease of use, and patient comfort. The O-scan Premium is the extremity MRI of choice for sites that require high throughput, improved workflow and advanced applications. The O-scan Light is the perfect choice for high quality MRI with an emphasis on overall value and economic.

“The introduction of the expanded range of O-scan Extremity MRI Systems provides more choices for Healthcare Providers and Hospitals to provide high quality imaging directly to their patients,” states Glenn Davis, President and General Manager, of Esaote North America, Inc. “The O-scan offers a complete range of high quality imaging capabilities for extremities whilst providing an optimal patient experience, thanks to its unique ergonomics and open design.”

Powered by the eXP technology, the O-scan Premium offers exceptional image quality, patient throughput, optimized workflow and faster scan times in both private practice, clinics and hospital setting, specifically targeted to Orthopedic Surgeons, Radiologists, and Rheumatologists. The O-scan Light represents an affordable choice without compromise, specially designed to meet the image quality, easy workflow and patient comfort expectations required for Podiatry private practices. With unique image optimization and advanced diagnostic tools, and Italian engineering and design, clinicians can quickly acquire exceptional images for increased diagnostic confidence.

About Esaote: With a consolidated turnover of EUR 270 million in 2016, the Esaote Group is a leader in the biomedical equipment sector, in particular the areas of ultrasound, dedicated MRI and software for managing the diagnostic process. The Group currently employs 1,200 people. With its own production and research units in Italy and the Netherlands, Esaote is recognized as one of the top 10 diagnostic imaging companies in the world.

Esaote will be exhibiting the O-scan Premium and O-scan Light at AAOE 2018 Annual Conference.

Esaote@AAOE 2018:  Esaote will be exhibiting at AAOE 2018- American Association of Orthopaedic Executives 2018, April 14th – April 17th, 2018.

LOCATION:

Hyatt Regency Orlando, Orlando, FL – AAOE 2018 – Booth #219

* Technology and features are system/configuration dependent. Specifications are subject to change without notice. Information might refer to products or modalities not yet approved in all countries. For further details, please contact your Esaote sales representative.

Contact lrojas@esaoteusa.com

SOURCE Esaote North America

Related Links

https://www.esaoteusa.com

Orthopaedic Surgeons Offer Laser Therapy For Pain Management And Find Great Success

 

Stryker F1™ Small Bone Power System brings fresh innovation to the power tool market

KALAMAZOO, Michigan, USA, March 23, 2018 /PRNewswire/ — Stryker’s Instruments division announced today the launch of the Stryker F1™ Small Bone Power System, providing surgeons with a cordless, balanced, lightweight solution for procedures of the extremities.

Until now, extremities surgeons have, for the most part, used cord-and-console setups. While a console delivers the requisite power for working with small bones, it also comes with unavoidable compromises. It reduces maneuverability, may break the sterile operating field and with multiple components, can make both operation and troubleshooting less efficient. The Stryker F1 System allows for the elimination of cords, hand switches, and consoles and provides a much more efficient way to perform distal extremity procedures.

The Stryker F1 System is powered by SmartGRIP™ Technology. Surgeons have the choice of two unique gripping styles – the pencil or pistol-style SmartGRIP. Each SmartGRIP is a lightweight, well- balanced battery control module that contains lithium ion cells and enables the surgeon to operate three micro saws, a micro drill, and a universal motor for inserting k-wires and drilling. The five motors and three attachments are interchangeable between SmartGRIP Control Module, allowing surgeons to choose their specific approach. Each SmartGRIP Control Module:

  • Can remain on the shelf, unused, for 30 days without losing power and performance1
  • Provides consistent power and uptime
  • Contains insulation to increase resistance to thermal damage during exposure to high temperatures throughout sterilization
  • Includes a battery indicator light to display SmartGRIP Control Module status information

In addition to delivering procedural efficiency, the Stryker F1 System will connect to Smart Equipment Management (SEM), a new online data module designed to help optimize the management of Stryker’s smart devices through device-derived, actionable data. The Stryker F1 System pairs exclusively with the Resurfacing Tool, an innovative cutting accessory that provides a reduced level of chatter, increased cut accuracy, and increased cut speed when compared to a 4.0mm fluted egg bur2.

The Stryker F1 system has a small footprint, making it a great addition to both hospitals and surgery centers, and provides an all-inclusive, non-anodized container with two tray inserts to hold every component in the system. This allows SmartGRIP Control Modules to be sterilized in multiple ways3 allowing facilities to choose the sterile processing option that best meets their needs.

The Stryker F1 system provides the necessary power to complete the indicated procedures using the gripping style that is most comfortable for the surgeon and allows them to operate at their best.

About Stryker
Stryker is one of the world’s leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. More information is available at www.stryker.com.

Media contact
Jennifer Lentner
Sr. Director, Marketing Communications
jennifer.lentner@stryker.com

1 Stryker engineering data on file. Kalamazoo, MI
2 The 2.5mm egg resurfacing tool (1900-015-025) had an equivalent cut speed when compared to the 4.0 mm fluted egg bur (1608-002-035). Under test lab conditions when compared to the 1608-002-035 using a bone substitute.
3 For complete cleaning and sterilization instructions, please refer to Stryker F1 Care Instructions.

SOURCE Stryker

Related Links

http://www.stryker.com

Wright Medical Group N.V. Highlights New Product Launches at the American College of Foot and Ankle Surgeons (ACFAS) 2018 Scientific Conference

AMSTERDAM, The Netherlands, March 22, 2018 (GLOBE NEWSWIRE) — Wright Medical Group N.V. (NASDAQ:WMGI) today announced that it will highlight new innovations at the American College of Foot and Ankle Surgeons (ACFAS) 2018 Scientific Conference taking place at the Gaylord Opryland Hotel in Nashville, Tennessee, from March 22-25, 2018.

Wright will feature its full range of lower extremities and biologic solutions at exhibit booth #244, including the INVISION™ Total Ankle Revision System with PROPHECY Preoperative Navigation, the first preoperative planning system with patient-specific instrumentation for ankle revision arthroplasty.  The introduction of INVISION with PROPHECY is an important addition to Wright’s total ankle portfolio, extending the use of preoperative planning to the entire continuum of care from primary through revision procedures.

“The INVISION Total Ankle Revision System with PROPHECY Preoperative Navigation builds on Wright Medical’s commitment to providing physicians with innovative tools that lead to the best possible patient outcomes,” said Robert Palmisano, President and Chief Executive Officer of Wright.  “Total ankle arthroplasties provide a unique set of challenges for our physicians and we are excited to be bringing this technology to market to see its success in action.  The launch of INVISION with PROPHECY expands our leadership in total ankle technology and marks our ability to best address the total ankle replacement continuum of care.”

The PROPHECY System was first approved for total ankle replacement in 2012 and has been clinically proven to help surgeons accurately align ankle replacements1 and increase surgical efficiency by reducing OR time and potentially cost2.  Developed from the patient’s own CT scan, implant sizing and alignment are determined using the patient’s unobstructed anatomic landmarks and the surgeon’s preferences. PROPHECY alignment guides are subsequently created, providing patient-specific instruments to help the surgeon precisely position implants while reducing surgical steps, which in turn allows for less procedural complexity and surgery time.

“Revision of a failed total ankle arthroplasty remains a challenge,” said Dr. William McGarvey, Chief of Foot and Ankle Surgery at the McGovern Medical School at the University of Texas Health Science Center – Houston, who has performed several revision procedures with PROPHECY to date.  “The ability to preoperatively plan out these cases and determine appropriate alignment based on the individual patient’s CT data will provide surgeons with an extra level of confidence that the implants will be positioned in the optimal alignment.”

Key benefits of PROPHECY now include:

  • Full array of implant choices (INFINITY™, INBONE™ or INVISION™) to fit the patient’s specific needs
  • Ability to create a detailed revision surgical plan with or without failed implants currently in place
  • 3D visualization of how to manage bone loss and reconstruct joint height under unique revision conditions

Recent new products to be featured at ACFAS include:

INVISION™ Total Ankle Revision System – The first and only system developed specifically for total ankle revision arthroplasty, the INVISION Total Ankle Revision System provides a unique solution for even the most difficult revision procedures. Whether leveraged as a standalone construct or in conjunction with INFINITY and INBONE components, the INVISION Total Ankle Revision System is an important addition to the continuum of care from total ankle replacement through any necessary revisions. The INVISION Total Ankle Revision System helps surgeons re-build bone lost through previous surgeries and provides modularity to help restore natural joint height.

ORTHOLOC™ 3Di Ankle Fracture Low Profile System – The ORTHOLOC 3Di Ankle Fracture Low Profile System features a complete range of ankle fracture plates designed specifically for the foot and ankle surgeon. The system features low-profile, anatomic plate designs and ORTHOLOC 3Di polyaxial locking screw technology, providing an innovative fracture solution that addresses a primary need for one of the foot and ankle’s largest market segments.

For more information about Wright Medical’s portfolio of total ankle products, visit: www.totalankleinstitute.com

1 Hsu AR, Davis WH, Cohen BE, Jones CP, Ellington JK, Anderson RB. Radiographic outcomes of preoperative CT scan-device patient-specific total ankle arthroplasty. Foot Ankle Int 2015;36:1163-1169.
2 Hamid KS, Matson AP, Nwachukwu BU, Scott DJ, Mather RC, DeOrio JK. Determining the cost-savings threshold and alignment accuracy of patient-specific instrumentation in total ankle replacements. Foot Ankle Int 2016;38:49-57.

Internet Posting of Information

Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com.  The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright.

About Wright Medical Group N.V.

Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products.  The company is committed to delivering innovative, value-added solutions improving quality of life for patients worldwide and is a recognized leader of surgical solutions for the upper extremity (shoulder, elbow, wrist and hand), lower extremity (foot and ankle) and biologics markets, three of the fastest growing segments in orthopedics.  For more information about Wright, visit www.wright.com.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this release include, but are not limited to, statements about the performance and market acceptance of the company’s products. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, physician acceptance, endorsement, and use of company products; the effect of regulatory actions, changes in and adoption of reimbursement rates; product liability claims; product recalls; the effects of industry, economic or political conditions outside of the company’s control; competitor activities; and the risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form 10-K for the year ended December 31, 2017 filed by Wright with the SEC on February 28, 2018 and in other subsequent SEC filings by Wright. Investors should not place considerable reliance on the forward-looking statements contained in this release. Investors are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this release speak only as of the date of this release, and Wright undertakes no obligation to update or revise any of these statements. Wright’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Investors & Media:

Julie D. Tracy
Sr. Vice President, Chief Communications Officer
Wright Medical Group N.V.
(901) 290-5817
julie.tracy@wright.com

OrthoPediatrics Corp. Introduces PediFlex™ Advanced Surgical System

WARSAW, Ind., March 22, 2018 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (NASDAQ:KIDS), a company exclusively focused on advancing the field of pediatric orthopedics, is pleased to announce the introduction of PediFlex™ Advanced, the Company’s next generation elastic nailing platform. The upgrade to the legacy system provides a modified flexible nail implant in multiple diameters and lengths, available in both stainless steel and titanium. The platform includes an innovative new inserter design, allowing for easy assembly and interchangeable collets for multiple nail sizes. Further, PediFlex™ Advanced features enhanced instruments for nail extraction and completes the next step in the evolution of OrthoPediatrics’ intramedullary nailing franchise.

Joe Hauser, OrthoPediatrics’ Vice President of Trauma & Deformity Correction, stated, “We are committed to providing pediatric orthopedic surgeons with the most innovative systems to treat their patients, and flexible nailing is one of the most frequent pediatric implant procedures. The enhancements beyond the first generation PediFlex Nail System provide a significant advancement in pediatric fracture care. Additionally, this expansion represents OrthoPediatrics’ commitment to continuous improvement of its products.”

About PediFlex™ Advanced
PediFlex™ Advanced is intended for fixation of diaphyseal fractures of long bones where the medullary canal is narrow or flexibility of the implant is required. This includes upper extremity fractures in all patients and lower extremity fractures in pediatric or small stature patients. In pediatric patients, the flexibility of the nail allows it to be inserted at a point that does not disturb or disrupt the growth plate.

About OrthoPediatrics Corp. 
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on providing a comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 24 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This offering spans trauma & deformity, scoliosis and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 37 countries outside the United States.

Investor Contacts
The Ruth Group
Tram Bui / Emma Poalillo
(646) 536-7035 / 7024
tbui@theruthgroup.com / epoalillo@theruthgroup.com

Mark Foster Named President of Trice Medical

Trice Medical today announced the appointment of Vice President of Worldwide Sales and Chief Commercialization Officer, Mark Foster as President and CCO. Mr. Foster will retain his role as Chief Commercialization Officer and assume the duties and responsibilities of President from Jeffrey F. O’Donnell, Sr., who will remain the Company’s CEO.

“Mark has demonstrated tremendous leadership and management skills,” stated Jeffrey F. O’Donnell, Sr., Trice’s CEO. “Our Board of Directors admires his ability to execute and motivate teams to success. Mark will assume the role of President of the organization worldwide. I am looking forward to working with Mark to continue building the value of Trice Medical.”

Foster joined Trice in 2016, serving as VP of WW Sales and CCO. In that role, Foster led the Company’s product commercialization and sales worldwide, working closely with the product development, operations, sales, and marketing teams to solidify Trice Medical’s position as a leader in the orthopedic industry.

“I am honored and energized for the opportunity to further shape the direction of the organization. Trice has developed a dynamic imaging system that can deliver instant answers to patients, payors, and providers. It’s rare to find a platform that can bring value to all three of those stakeholders. The mi-eye two allows patients to get a dynamic evaluation of their knee or shoulder in an office setting, and to have their injections delivered under direct visualization, ensuring accurate placement. I’m looking forward to working with our team to find even more ways to deliver products that excite our customers,” said Foster.

Prior to Trice, Foster spent eight years with Smith & Nephew, a global medical technology company. His last position with Smith & Nephew was Vice President, U.S. Sports Medicine in the Advanced Surgical Device Division. Earlier in his career, Foster spent eight years with Boston Scientific in several different leadership roles. He started his healthcare career with Smith Kline Beecham. He holds a B.A. from the University of Richmond.

About Trice Medical

Trice Medical was founded to fundamentally improve orthopedic diagnostics for the patient and the physician by providing instant answers. Trice has pioneered fully integrated camera-enabled technology, the mi-eye 2, which provides a clinical solution optimized for the physician’s office. Trice Medical’s mission is to provide more immediate and definitive patient care, eliminating the false reads associated with current indirect modalities and significantly reduce the overall cost to the healthcare system.

For Inquires contact:

Cathy Whetstone

email: info@TriceMedical.com

Phone: +1 (610) 989 – 8080

Tyber Medical Announces the Limited Release of the Sterile Comprehensive Forefoot Procedure Kit

BETHLEHEM, Pa.March 21, 2018 /PRNewswire/ — Tyber Medical, LLC, a privately held company focusing on developing innovative medical devices for private label opportunities and advancing the science of bioengineered surfaces, announces the limited release of the Forefoot Procedure Kit.

Tyber Medical is excited to announce the limited release of the Forefoot Procedure Kit. This innovative system is the first efficiency kit on the market to incorporate room setup disposables, instruments for soft tissue, bone and implant preparation, and the corresponding implants. The system configuration allows for flexibility in the treatment of a wide range of fixation procedures including bunion corrections, hammertoes, Aikens as well as Weil’s osteotomies. This unique one of kind system is provided sterile to increase efficiency in the Operating Room.

The complete kit eliminates the necessity for cleaning, decontamination, sterilization, and reprocessing thereby reducing direct and indirect costs while accelerating room turnover to create a more efficient center.  All implants are sterile, ready-to-use, and include headed or headless screws, TyFix™ hammertoe screws, snap-off screws, as well as NiTiNOL staples in various sizes to suit any type of Forefoot procedure.

Catye Mullens, a Certified Surgical Technician in Materials Management at Wilshire Surgery Center and a member of the design team stated, “The Forefoot Procedure Kit is a time saver for OR setups and comes with all the fundamental items we need and nothing we don’t. We also appreciate the efficient space management design which minimizes shelf requirements for our surgery center.”  Donna Faillace, a Certified Surgical Technician at Providence Health Center commented “The Forefoot Procedure Kit makes it so easy to set up for surgeries knowing everything our surgical team and center needs is included.  It decreases turnover time because you’re not waiting for instruments to process and the surgeon is pleased because he has consistent equipment available for every case.”

“The Forefoot Procedure Kit was designed to be an inclusive system delivering a procedure in a box while allowing the surgeon flexibility to create any type of Forefoot reconstructive procedure. The kit aligns efficiency and effectiveness together to offer a solution for cost reduction, time efficiencies, and better organization of pre-operative planning,” commented Jeff Tyber, CEO of Tyber Medical.

Tyber Medical continues to focus on systems designed to drive pre-operative, intra-operative, and post-operative efficiency, while embracing system improvements that could lead to a lower rate of surgical field contamination and subsequent patient infections.  Please visit Tyber Medical’s Booth #333, at ACFAS in Nashville, TN where the company will showcase the Forefoot Procedure Kit and recently released TyFix™ System as well as other innovative products available for private labeling.

About Tyber Medical, LLC.

Tyber Medical, LLC is an orthopedic device manufacturer providing rapid access to portfolio enhancing, regulatory approved, orthopedic implants within the spine and extremity/trauma markets.  While focusing on rapid product commercialization, the company distributes products via private labeling; releasing 14 spine and 25 extremity/trauma systems since its founding in 2012.  Tyber Medical utilizes the differentiated, bioengineered technology such as TyPEEK® osteoconductive coatings and BioTy™, a new antimicrobial nano-textured surface modification to enhance the company’s growing portfolio.

Contact:
Eric Dickson
83 South Commerce Way, Suite 310
Bethlehem PA 18017
(610) 849-1710
edickson@tybermed.com

SOURCE Tyber Medical, LLC

Related Links

http://www.tybermedical.com

Smith & Nephew Supports AAFAO Courses with Donation of More Than $3M of Equipment to The Podiatry Institute

LONDONMarch 19, 2018 /PRNewswire/ — Smith & Nephew (NYSE: SNN; LSE:SN), the global medical technology business, today announces the donation of more than $3M of trauma plates and screws, external fixation implants and instruments to The Podiatry Institute (PI). This equipment will be used to support ongoing educational courses conducted at the PI through the American Academy of Foot and Ankle Osteosynthesis (AAFAO).

Smith & Nephew has been the sole sponsor of the comprehensive and advanced educational courses conducted by the PI and AAFAO for the past four years, contributing to resident education for nearly 1600 participants. The company not only provided the surgical equipment and personnel support for these courses, but also hosted the event at its world class Innovation Center in Memphis, Tenn.

“Smith & Nephew has always been proud to support this important training. We view this donation as an important business need for podiatric resident training and their future patients,” said John Clausen, Vice President Global Marketing, Trauma and Extremities. “Along with this donation of surgical equipment, we will also continue to provide support with the appropriate Smith & Nephew personnel.”

The AAFAO was founded in 2014 for the sole purpose of training podiatric residents in the techniques and skills of skeletal fixation, trauma and reconstructive surgery of the foot and ankle. Courses are led by some of the best podiatrists in the profession with curriculum covering application of the principles and techniques for current and novel approaches to reconstructive surgery on the foot and ankle. This donation allows the AAFAO and PI to host these courses multiple times a year while opening up opportunities for multiple sponsors.

About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound ManagementSports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2017 were almost $4.billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.comfollow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward- looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.

™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.

SOURCE Smith & Nephew

Related Links

http://www.smith-nephew.com